Eupraxia Pharmaceuticals Inc
Research Eupraxia Pharmaceuticals Inc (EPRX) on Bullrun: market cap CAD 612.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEPRX
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 612.93M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 12.65M
- Free cash flow-USD 10.47M
Valuation Snapshot
latest market cap is CAD 612.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 38.58M | -USD 29.14M | n/a | n/a | USD 80.56M | USD 154.36K | USD 82.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 612.93M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eupraxia Pharmaceuticals Inc's market cap?
Eupraxia Pharmaceuticals Inc's market capitalization is CAD 612.93M.
What does Eupraxia Pharmaceuticals Inc do?
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.